Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Fighting TB battle: FDA advisory panel recommends approval of TB Alliances tuberculosis treatment

      Fighting TB battle: FDA advisory panel recommends approval of TB Alliance's tuberculosis treatment

      Medical Dialogues Bureau7 Jun 2019 2:53 PM IST
      Independent experts of an FDA advisory panel voted in favour of the not-for-profit TB Alliance's treatment for drug-resistant tuberculosis, as a part...
      Alembic Pharma gets USFDA nod for Carbidopa and Levodopa extended-release tablets for Parkinsons treatment

      Alembic Pharma gets USFDA nod for Carbidopa and Levodopa extended-release tablets for Parkinson's treatment

      Medical Dialogues Bureau7 Jun 2019 2:23 PM IST
      New Delhi: Alembic Pharmaceuticals on Thursday informed it has received approval from the US health regulator for Carbidopa and Levodopa...
      Natco Pharma- Kothur facility gets 9 observations from USFDA

      Natco Pharma- Kothur facility gets 9 observations from USFDA

      Medical Dialogues Bureau7 Jun 2019 2:21 PM IST
      NEW DELHI: Natco Pharma Thursday said the US health regulator has made nine observations after the completion of inspection of its Kothur formulation...
      Marksans Pharma gets EIR from USFDA for its Goa facility

      Marksans Pharma gets EIR from USFDA for its Goa facility

      Medical Dialogues Bureau7 Jun 2019 2:20 PM IST
      New Delhi: Drug firm Marksans Pharma Thursday said it has received Establishment Inspection Report (EIR) from the US health regulator for its Goa...
      Japanese regulator PMDA completes inspection of Lupin Mandideep facility unit, no major observations

      Japanese regulator PMDA completes inspection of Lupin Mandideep facility unit, no major observations

      Medical Dialogues Bureau6 Jun 2019 2:05 PM IST
      New Delhi: Drug firm Lupin Tuesday said Japanese regulatory agency, PMDA, has concluded the inspection of Unit 2 at Mandideep facility in Madhya...
      Eli Lilly Bags USFDA nod for its migraine drug as first ever cluster headache treatment

      Eli Lilly Bags USFDA nod for its migraine drug as first ever cluster headache treatment

      Medical Dialogues Bureau6 Jun 2019 1:27 PM IST
      NEW YORK: Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of...
      Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

      Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

      Medical Dialogues Bureau6 Jun 2019 9:22 AM IST
      Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it...
      Healthcare Startup Pristyn Care raises Rs 27 crore funding from Sequoia India

      Healthcare Startup Pristyn Care raises Rs 27 crore funding from Sequoia India

      Medical Dialogues Bureau5 Jun 2019 2:36 PM IST
      New Delhi: Healthcare delivery startup Pristyn Care Monday said it has raised USD 4 million (about Rs 27.7 crore) in funding from Sequoia...
      Experts differ on ICMR suggestion on banning e-cigarettes, ENDS devices

      Experts differ on ICMR suggestion on banning e-cigarettes, ENDS devices

      Medical Dialogues Bureau5 Jun 2019 12:45 PM IST
      New Delhi: A section of experts have said banning Electronic Nicotine Delivery Systems (ENDS), including e-cigarettes, without proper research will...
      Fortis Healthcare gets BSE,NSE nod for reclassification of promoters

      Fortis Healthcare gets BSE,NSE nod for reclassification of promoters

      Medical Dialogues Bureau5 Jun 2019 12:39 PM IST
      NEW DELHI: Fortis Healthcare on Monday said it has received approval from both bourses BSE and NSE for reclassification of its promoters including...
      Aurobindo Pharma gets 10 observations from USFDA for its Unit 3 at Hyderabad

      Aurobindo Pharma gets 10 observations from USFDA for its Unit 3 at Hyderabad

      Medical Dialogues Bureau5 Jun 2019 12:28 PM IST
      New Delhi: Drug firm Aurobindo Pharma Tuesday said it has received 10 observations from the US health regulator for its Unit 3 in Hyderabad.The United...
      Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug

      Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug

      Medical Dialogues Bureau5 Jun 2019 12:27 PM IST
      Hyderabad: Swiss pharma company Actelion Pharmaceuticals Ltd has filed a petition in a US court alleging that Natco Pharma and its US partner Syneos...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok